Letter to Shareholders from CEO Dr. Ryan Saadi

$TVGNPress releaseMay 18, 2026, 12:15 PM ETRead the release

Tevogen CEO Ryan Saadi reported a 51% decline in full-year operating losses, dropping from $53.6 million in 2024 to $26.1 million in 2025. Q1 2026 operating loss further improved to $5.4 million, a 48% reduction compared to the same period in 2025.

Key figures

Operating loss 2024: 53600000
Operating loss 2025: 26100000
Operating loss q1 2026: 5400000

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $40.67/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.